$OABI

$OABI stock is up 10% today. Here's what we see in our data.

OABI stock rose 10% today with $4.3M in trading volume. Insiders sold 33,314 shares in the past 6 months. 78 hedge funds increased holdings, while 66 decreased. Notable moves include Nomura Holdings adding 4.3M shares and Whitefort Capital Management removing 3.9M shares.

Original reporting
Published Sep 14, 2026, 7:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
$OABI stock is up 10% today. Here's what we see in our data. — source image
Decision brief

The 30-second read

$OABINeutralLow
01

Why it matters

Provides a snapshot of ownership changes but lacks a fresh, material catalyst; traders should treat the data as informational rather than actionable.

02

Market read

Only OABI is directly affected; the broader market sees no significant impact.

03

What to watch

Absence of a clear catalyst suggests the move may be speculative or driven by short‑term trading dynamics.

Relevance 4/10Novelty 2/10Timing: today

Background

The piece aggregates recent insider transactions and hedge‑fund holdings for OABI, a US‑listed biotech company.

Company-level read

Ticker impact

$OABINeutralLow confidence
Context

The article reports a 10% intraday price rise and details recent insider sales and hedge‑fund position changes for OABI.

Expected impact

Potential modest pull‑back as insiders continue selling.

Evidence & confidence

No new catalyst beyond the price move; data is aggregated and may already be priced in.

Market effects

Limited; the biotech/health‑care sector sees no broader news from this report.

Minimal impact on US markets beyond OABI's own stock.

None

Counterpoint

The 10% rise may be a short‑term overreaction; continued insider sales could drive the stock lower.

Key entities

  • OABI

    US‑listed biotech firm (ticker OABI).

Related articles

$OABIMedAI 8/10

OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook

OmniAb Inc. (OABI) shares rose about 18% in premarket after the company increased its 2026 cash forecast. OmniAb now expects $49 million to $53 million in cash and cash equivalents, up from $37 million to $41 million, citing recent license and business-development agreements, including a technology contract with Eli Lilly for its ion-channel program.

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$OABIMed

OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook

OmniAb Inc. (NASDAQ: OABI) shares rose about 21.6% after the company reported a Q2 earnings beat and raised 2026 revenue guidance to $32M–$36M from $28M–$33M. The article cites Q2 revenue around $13.4M, gross margin near 99.9%, and positive operating and free cash flow. It also notes a Veraxa Biotech collaboration on VXA-222.

$OABIHighAI 9/10

Why is OmniAb stock surging today?

Investing.com reports OmniAb’s shares rose 22.5% in pre-open trading to $4.14, above its prior 52-week high of $3.635. The company announced a global collaboration and license with Eli Lilly for an ion channel drug discovery program, with an upfront payment and up to $370M in milestones plus tiered royalties. OmniAb also raised 2026 cash guidance to $49M-$53M from $37M-$41M.